Neuroendocrine Tumors
Ursula Plöckinger(Charité - Universitätsmedizin Berlin), Marianne Pavel(Universitätsklinikum Erlangen), Roelf Valkema(Active Medicine (United Kingdom)), Anja Rinke, Christoph J. Auernhammer(LMU Klinikum), Guido Rindi(Agostino Gemelli University Polyclinic), Wouter W. de Herder(Erasmus University Rotterdam), Jaap J.M. Teunissen(Erasmus MC), Anders Sundin, Gregory Kaltsas(National and Kapodistrian University of Athens), Dermot O’Toole(Trinity College Dublin), Rossella Bettini(Policlinico Universitario di Catania), Boen L.R. Kam(Erasmus MC), Per Hellman(Uppsala University Hospital), Μ. Rothmund(Philipps University of Marburg), Frédérique Maire(Université Paris Cité), Göran Åkerström(Uppsala University), Michael Olausson(University of Gothenburg), P. Ruszniewski(Université Paris Cité), Cesare Bordi(University of Parma), Dimitios Papdogias(General Hospital of Athens G. Genimatas), Håkan Ahlman(University of Gothenburg), Dik J. Kwekkeboom(Erasmus MC), Eric P. Krenning(Cyclotron (Netherlands)), Rudolf Arnold(Philipps University of Marburg), Gianfranco Delle Fave(CTO Andrea Alesini), Massimo Falconi(Vita-Salute San Raffaele University), Barbro Eriksson
Cited by 2
Related Papers
Phase 3 Trial of <sup>177</sup> Lu-Dotatate for Midgut Neuroendocrine Tumors
|New England Journal of Medicine|2017|3.2k
Detection and localization of surgically resectable cancers with a multi-analyte blood test
|Science|2018|2.8k
Gastroenteropancreatic neuroendocrine tumours
|The Lancet Oncology|2008|1.8k
Treatment With the Radiolabeled Somatostatin Analog [ <sup>177</sup> Lu-DOTA <sup>0</sup> ,Tyr <sup>3</sup> ]Octreotate: Toxicity, Efficacy, and Survival
|Journal of Clinical Oncology|2008|1.4k